Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: NPS Pharmaceuticals, Inc.(NASDAQ:NPSP), Zimmer Holdings, Inc.(NYSE:ZMH), Forest Laboratories, Inc.(NYSE:FRX), Nektar Therapeutics (NASDAQ:NKTR)
NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) managed to keep its gain at 0.26% on below-normal volume of 1.22M shares. The stock settled at $34.79 after floating in a range of $34.73 to $35.49. Its latest price has reached market capitalization of $3.53B. Its 52-week range has been $7.35 to $35.72. NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Is NPSP Ready To Move Up? Find Out Here
Zimmer Holdings, Inc.(NYSE:ZMH) traded on a volume of 1.21M Shares, higher than its standard daily volume. Shares have closed at $83.39. Over the last twelve months, the stock has gained 25.1% and faced a worst price of $61.97. Zimmer Holdings, Inc. (Zimmer) designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products.
Is ZMH a Solid Investment at These Levels ? Read This Report for Details
Forest Laboratories, Inc.(NYSE:FRX) settled up at $43.27 on above-normal volume of 1.19M shares during the last trading day. The stock has its 12-month high at $44.96 and 52-week low price was $31.71. It traded in a range of $42.91 to $43.47 during the last trading day. Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription.
Is FRX a Solid Investment at These Levels? Just Go Here and Find Out
In the last trading session, Nektar Therapeutics (NASDAQ:NKTR) was on low volume, trading at a volume of 1.16M versus its average daily volume of 1.53M shares. At $10.68, the stock has attained market capitalization of 1.24B. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Will Investors Buy NKTR After Reading This News? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)